Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Accumulated Expenses: 2019-2025

Historic Accumulated Expenses for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $24.2 million.

  • 4D Molecular Therapeutics' Accumulated Expenses rose 12.95% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year increase of 12.95%. This contributed to the annual value of $18.9 million for FY2024, which is 57.06% up from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Accumulated Expenses stood at $24.2 million for Q3 2025, which was up 26.05% from $19.2 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' Accumulated Expenses' 5-year high stood at $24.2 million during Q3 2025, with a 5-year trough of $4.9 million in Q2 2021.
  • Over the past 3 years, 4D Molecular Therapeutics' median Accumulated Expenses value was $12.8 million (recorded in 2024), while the average stood at $14.2 million.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Accumulated Expenses decreased by 7.49% in 2021, and later skyrocketed by 110.07% in 2024.
  • Over the past 5 years, 4D Molecular Therapeutics' Accumulated Expenses (Quarterly) stood at $7.7 million in 2021, then increased by 14.54% to $8.9 million in 2022, then soared by 35.45% to $12.0 million in 2023, then skyrocketed by 57.06% to $18.9 million in 2024, then rose by 12.95% to $24.2 million in 2025.
  • Its Accumulated Expenses stands at $24.2 million for Q3 2025, versus $19.2 million for Q2 2025 and $16.2 million for Q1 2025.